Evidence map›Paper›PMID 39643752›Full record

ArticleBreast cancer research and treatment2025

Inference of genetic ancestry from a multi-gene cancer panel in Colombian women with cancer.

Yina T Zambrano-O, Alejandro Mejía-Garcia, P Daniela Morales, Hsuan Megan Tsao, Laura Rey-Vargas, Wendy Montero-Ovalle, Carlos A Huertas-Caro, M C Sanabria-Salas, Julián Riaño-Moreno, Juliana L Rodriguez and 4 more

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yina T Zambrano-O *Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia. ytzambrano@cancer.edu.co.
Alejandro Mejía-Garcia *Department of Human Genetics, McGill University, Montreal, Canada.
P Daniela MoralesGrupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia.
Hsuan Megan TsaoDepartment of Human Genetics, McGill University, Montreal, Canada.
Laura Rey-VargasGrupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia.
Wendy Montero-OvalleGrupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia.
Carlos A Huertas-CaroGrupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia.
M C Sanabria-SalasGrupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia.
Julián Riaño-MorenoDepartamento de Patología y Oncología Molecular, Instituto Nacional de Cancerología, Bogotá, Colombia.
Juliana L RodriguezGrupo de Investigación Clínica y Epidemiológica, Instituto Nacional de Cancerología, Bogotá, Colombia.
Carlos A OrozcoGrupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia.
Liliana Lopez-KleineGrupo de Investigación en Bioinformática y Biología de Sistemas, Departamento de Estadística, Universidad Nacional de Colombia, Bogotá, Colombia.
I King JordanBioinformatics Department, Georgia Institute of Technology, Atlanta, USA.
Silvia J Serrano-GGrupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología, Cl. 1 #9-85, Bogotá, Colombia. silviajserrano@gmail.com.

Funding

Instituto Nacional de Cancerología MCSS-SJSGC19010300455
6 · The paper itself

Abstract

introductionCancer health disparities among racial and ethnic populations significantly burden health systems due to unequal access to early detection, treatment, and healthcare resources. These disparities lead to worse outcomes and increased costs from delayed diagnoses, advanced treatments, and prolonged care. Genetic differences can also influence cancer susceptibility and treatment response, thus analyzing genetic ancestry is essential for uncovering genetic factors that may contribute to these disparities. Utilizing data from clinical multigene cancer panels to infer genetic ancestry offers a valuable approach to understand population structure and the impact of individual ancestries in development of complex diseases.

aimTo evaluate the accuracy of global ancestry inference using genetic markers from the TruSight™ Hereditary Cancer Panel, which was used to investigate hereditary cancer syndromes in a cohort of 116 female cancer patients at the Colombian National Cancer Institute. Additionally, to compare these results with genetic ancestry estimations from traditional genome-wide markers.

resultsOur results demonstrate a strong correlation between global genetic ancestry inferred with markers captured from TruSight

conclusionThis study demonstrates the accuracy of ancestry inference from clinical panel data offering a promising approach for understanding cancer health disparities in admixed populations.

Indexed as

Biomarkers, TumorBreast NeoplasmsNeoplasmsAdultAgedColombiaFemaleGenetic MarkersGenetic Predisposition to DiseaseHumansMiddle AgedWhole Genome SequencingBiomarkers, TumorGenetic MarkersAdmixed populationsClinical panelsDiversityGenetic ancestry

Identifiers

PMID39643752
PMCPMC11930861

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.